Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 127, doi. 10.2147/PTT.S510141
- By:
- Publication type:
- Article
Works matching IS 2230326X AND DT 2025 AND VI 15
Results: 15
1
2
Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 145, doi. 10.2147/PTT.S514249
- By:
- Publication type:
- Article
3
Psoriasis: Prevalence, Clinical Variants and Quality of Life, Among Patients Attending the Skin Clinic at Mbarara Regional Referral Hospital, Uganda.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 117, doi. 10.2147/PTT.S497092
- By:
- Publication type:
- Article
4
Predictors of Quality of Life in Psoriasis Patients: Insights from a Cross-Sectional Study.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 163, doi. 10.2147/PTT.S516109
- By:
- Publication type:
- Article
5
Dual Biologic Therapy for Psoriasis in a Patient with Atopic Dermatitis.
- Published in:
- 2025
- By:
- Publication type:
- Case Study
6
Treatment With Schistosoma Japonicum Peptide SJMHE1 and SJMHE1-Loaded Hydrogel for the Mitigation of Psoriasis.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 85, doi. 10.2147/PTT.S506624
- By:
- Publication type:
- Article
7
Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 71, doi. 10.2147/PTT.S509495
- By:
- Publication type:
- Article
8
A Randomized Controlled Trial for the Optimal Implementation of Psoriasis Treatment by Integrating Chinese and Western Medicine.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 55, doi. 10.2147/PTT.S487536
- By:
- Publication type:
- Article
9
Metagenomics Analysis of Altered Gut Microbiome in Psoriasis and the Mediation Analysis: A Case-Control Study.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 45, doi. 10.2147/PTT.S505283
- By:
- Publication type:
- Article
10
Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 29, doi. 10.2147/PTT.S502296
- By:
- Publication type:
- Article
11
Analysis of the Reduction in the Duration of Sick Leave for 32,512 Psoriasis Patients Following the Integration of Targeted Therapies for Psoriatic Disease into the Brazilian Healthcare System: a Retrospective Cohort Study.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 105, doi. 10.2147/PTT.S513878
- By:
- Publication type:
- Article
12
Acrodermatitis Continua of Hallopeau and Generalised Pustular Psoriasis: Case Reports of Two Different Manifestations of IL36RN Mutation in Siblings.
- Published in:
- 2025
- By:
- Publication type:
- Case Study
13
Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report.
- Published in:
- 2025
- By:
- Publication type:
- Case Study
14
Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 9, doi. 10.2147/PTT.S486338
- By:
- Publication type:
- Article
15
Breakthrough Psoriasis in Patients Receiving Biologicals.
- Published in:
- Psoriasis: Targets & Therapy, 2025, v. 15, p. 1, doi. 10.2147/PTT.S502382
- By:
- Publication type:
- Article